The QP19 peptide antigen was predicted to bind to I-Ad/I-Ed, the MHC Class II molecules of BALB/c; however, it elicited an ex-vivo gamma-IFN T cell ELISpot response and this response was associated with slower tumor growth rates. The gene discussed is IFNG; the disease is neoplasm.